Quantcast

Latest Diabetic foot Stories

2009-05-06 16:37:00

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of the Excellarate(TM) product candidate for the potential treatment of non-healing foot ulcers in patients with type I or type II diabetes. Excellarate is designed to require only one or two physician-administered treatments, in...

2009-05-05 07:00:00

ADDISON, Texas, May 5 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal(TM) Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal. The article, which is the first peer-review publication detailing clinical experience using Altrazeal(TM), was authored by a team of clinicians and scientists working at Southern Arizona Limb Salvage Alliance ("SALSA") at the...

2009-04-20 13:59:39

Treatment of chronic wounds is a continuing clinical problem and socio-economic burden with diabetic foot ulcers alone costing the NHS £300 million a year. Scientists in Bristol have found that human fetal stem cells can effectively be used to treat back leg ischaemic ulcers in a model of type 1 diabetes. The researchers also found the culture in which the stem cells had been grown mimicked the wound-healing ability of the cells, suggesting that they could be used as a "factory" of...

2009-04-06 08:00:00

TUCSON, Ariz., and GILROY, Calif., April 6 /PRNewswire/ -- The Department of Surgery at The University of Arizona College of Medicine and OmegaGenesis, Inc., announced an agreement to collaborate on potential remedies to address diabetic foot ulcers. The agreement includes joint work in support of potential remedies and to identify effective ways to provide information and education to medical professionals and patients globally. Diabetic foot ulcers are painful, open sores that develop...

2009-03-20 08:30:00

-- Accepted Abstract on CellerateRx Conducted by Dr. Matt Regulski -- FORT WORTH, Texas, March 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is exhibiting at DFCon 09 on March 19-21, 2009 at the Renaissance Hollywood Hotel in Los Angeles, California. DFCon is considered the premier international multidisciplinary diabetic foot conference that attracts attendees from more than...

2009-03-18 07:00:00

ADDISON, Texas, March 18 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex(TM) Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, CaliforniaMarch 19-21. The work will be presented on posters that will be on display during the meeting. Clinical evidence will be presented on a poster titled, "Nanoparticulate...

2009-03-13 16:25:00

ADDISON, Texas, March 13 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company's Scientific Advisory Board. Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. He also serves as the President and Chief Operating Officer of...

2009-02-13 06:30:00

Eleven of eleven wounds healed in 6 weeks or less PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that its MEDIHONEY Dressings were the focus of a case series on eleven non-healing venous leg ulcers. These wounds had previously failed to heal while being managed with such therapeutic modalities as multi-layered compression, silver antimicrobial dressings, antibiotic therapy, and...

2008-11-03 12:00:26

PRINCETON, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (BULLETIN BOARD: DSCI) announced today the first study patient has been entered into the company's Phase II study of its drug candidate, DSC127. Enrollment of the 75-patient study, looking into the drug's ability to accelerate healing in diabetic foot ulcers, is expected to be completed within 12 months. Currently, 4 US facilities have signed on as clinical study sites, with an additional 15 sites pending contract...

2008-10-30 06:00:44

BETHESDA, Md., Oct. 30 /PRNewswire-USNewswire/ -- Nearly 246 million people across the globe battle diabetes and its complications every year. However, medical care for diabetes is often not sought in time to prevent serious amputations, according to a recent survey by the American Podiatric Medical Association (APMA). The APMA study, conducted by an independent research firm, found that 25 percent of the 600 people surveyed who had suffered an amputation from diabetes said they should...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.